Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Spero Therapeutics

14/03/2024 03:43

* Spero Therapeutics Inc  SPRO.OQ  reported quarterly
adjusted
earnings of 96 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of 55 cents.  The mean expectation of
three analysts for the quarter was for a loss of 10 cents per
share. Wall Street expected results to range from -29 cents to 5
cents per share.
    * Revenue rose 55% to $73.52 million from a year ago;
analysts
expected $18.63 million. 
    * Spero Therapeutics Inc's reported EPS for the quarter was
96
cents​.
    * The company reported quarterly net income of $51.19
million.
    * Spero Therapeutics Inc shares had risen by 12.9% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 300%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50 
This summary was machine generated from LSEG data March 14 at
03:42 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.10          0.96           Beat
 Sep. 30 2023      -0.03          0.04           Beat
 Jun. 30 2023      -0.34          -0.23          Beat
 Mar. 31 2023      -0.33          -0.25          Beat